Condition: Lymphoma · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
This description comes directly from the study's public registry record.
Alison Moskowitz, MD · 212-639-4839
Steven Horwitz, MD · 212-639-3045
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Active Not Recruiting |
| Northwestern Medicine (Data collection and specimen analysis) | Chicago, Illinois, United States | Active Not Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Active Not Recruiting |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Weill Cornell Medical College | New York, New York, United States | Active Not Recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02974647